Scholarlink

<p>In 2017, the United States Food and Drug Administration (FDA) granted the inaugural approval of chimeric antigen receptor T cell (CAR-T) therapy, marking the advent of a new era in cancer immunotherapy. However, the conventional ex vivo CAR‑T cell manufacturing workflow is complex and time consuming, resulting not only in high treatment costs and limited patient access, but also in effector differentiation of T cells and upregulation of exhaustion markers during prolonged in vitro expansion, which may impair the durability and antitumor activity of the cell product and reduce therapeutic efficacy. To enhance the efficacy and accessibility of CAR-T therapy, the strategy of in vivo generation of CAR cells has emerged as a prominent research focus, notwithstanding substantial technical challenges and its broad prospects. This review systematically summarizes the latest advances, technical challenges, and future trends of in vivo CAR-T therapy, with an emphasis on CAR mRNA molecular design, structural modifications, advancements in gene delivery technologies, and clinical applications, aiming to provide a comprehensive reference for related research.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vivo CAR-T therapy: from molecular design to precision delivery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月2日

查看全文
  • Huixian Li,
  • Wenjing Wen,
  • Xuan Zhao,
  • Gaofeng Liang

摘要

In 2017, the United States Food and Drug Administration (FDA) granted the inaugural approval of chimeric antigen receptor T cell (CAR-T) therapy, marking the advent of a new era in cancer immunotherapy. However, the conventional ex vivo CAR‑T cell manufacturing workflow is complex and time consuming, resulting not only in high treatment costs and limited patient access, but also in effector differentiation of T cells and upregulation of exhaustion markers during prolonged in vitro expansion, which may impair the durability and antitumor activity of the cell product and reduce therapeutic efficacy. To enhance the efficacy and accessibility of CAR-T therapy, the strategy of in vivo generation of CAR cells has emerged as a prominent research focus, notwithstanding substantial technical challenges and its broad prospects. This review systematically summarizes the latest advances, technical challenges, and future trends of in vivo CAR-T therapy, with an emphasis on CAR mRNA molecular design, structural modifications, advancements in gene delivery technologies, and clinical applications, aiming to provide a comprehensive reference for related research.

Graphical Abstract